TELA Bio (TELA) Liabilities and Shareholders Equity (2018 - 2026)
TELA Bio has reported Liabilities and Shareholders Equity over the past 8 years, most recently at $81.4 million for Q4 2025.
- For Q4 2025, Liabilities and Shareholders Equity fell 5.95% year-over-year to $81.4 million; the TTM value through Dec 2025 reached $287.8 million, up 5.95%, while the annual FY2025 figure was $81.4 million, 5.95% down from the prior year.
- Liabilities and Shareholders Equity for Q4 2025 was $81.4 million at TELA Bio, up from $61.6 million in the prior quarter.
- Over five years, Liabilities and Shareholders Equity peaked at $94.4 million in Q2 2023 and troughed at $51.3 million in Q2 2022.
- A 5-year average of $70.8 million and a median of $70.3 million in 2021 define the central range for Liabilities and Shareholders Equity.
- Biggest five-year swings in Liabilities and Shareholders Equity: soared 83.87% in 2023 and later crashed 39.28% in 2024.
- Year by year, Liabilities and Shareholders Equity stood at $62.5 million in 2021, then rose by 8.49% to $67.9 million in 2022, then grew by 15.02% to $78.0 million in 2023, then rose by 10.92% to $86.6 million in 2024, then dropped by 5.95% to $81.4 million in 2025.
- Business Quant data shows Liabilities and Shareholders Equity for TELA at $81.4 million in Q4 2025, $61.6 million in Q3 2025, and $67.5 million in Q2 2025.